Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab

Nature Communications

Volumn 6, Issue , 2015, Pages

  Mitsuhashi, Atsushi ^a   Goto, Hisatsugu ^a   Saijo, Atsuro ^a   Trung, Van The ^a   Aono, Yoshinori ^a   Ogino, Hirokazu ^a   Kuramoto, Takuya ^a   Tabata, Sho ^a   Uehara, Hisanori ^a   Izumi, Keisuke ^a   Yoshida, Mitsuteru ^a   Kobayashi, Hiroaki ^b   Takahashi, Hidefusa ^c   Gotoh, Masashi ^d   Kakiuchi, Soji ^a   Hanibuchi, Masaki ^a   Yano, Seiji ^e   Yokomise, Hiroyasu ^d   Sakiyama, Shoji ^a   Nishioka, Yasuhiko ^a,f  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b FUKUI KEN SAISEIKAI HOSPITAL   (Japan)

^c Tsuruga City Hospital   (Japan)

^d KAGAWA UNIVERSITY   (Japan)

^e KANAZAWA UNIVERSITY   (Japan)

^f JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CD34 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; COLLAGEN TYPE 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; INFIGRATINIB; INTERLEUKIN 17; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SCLEROPROTEIN; VASCULOTROPIN A; ANGIOGENESIS INHIBITOR;

BIOMARKER; CANCER; CELLS AND CELL COMPONENTS; COLLAGEN; TUMOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BONE MARROW CELL; CANCER RESISTANCE; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FIBROCYTE LIKE CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PLEURA MESOTHELIOMA; PROTEIN EXPRESSION; TUMOR CELL INOCULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DRUG RESISTANCE; FIBROBLAST; GENETICS; LUNG NEOPLASMS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; BEVACIZUMAB; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84949310071     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9792     Document Type: Article

References (69)

1. Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6, 273-286 (2007).
2. Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307 (2011).
3. Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nat. Med 9, 669-676 (2003).
4. Ferrara, N. & Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev. 18, 4-25 (1997).
5. Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N. Engl. J. Med. 355, 2542-2550 (2006).
6. Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
7. Montero, A. J. & Vogel, C. Fighting fire with fire: rekindling the bevacizumab debate. N. Engl. J. Med. 366, 374-375 (2012).
8. Rapisarada, A. & Melillo, G. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat. Rev. Clin. Oncol. 9, 378-390 (2012).
9. Ebos, J. M. & Kerbel, R. S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8, 210-221 (2011).
10. Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603 (2008).
11. De Bock, K., Mazzone, M. & Carmeliet, P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat. Rev. Clin. Oncol. 8, 393-404 (2011).
12. Murdoch, C., Muthana, M., Coffelt, S. B. & Lewis, C. E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8, 618-631 (2008).
13. Lin, E. Y. et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 66, 11238-11246 (2006).
14. Shojaei, F. et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 25, 911-920 (2007).
15. Cascone, T. et al. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J. Clin. Invest. 121, 1313-1328 (2011).
16. Bottsford-Miller, J. N., Coleman, R. L. & Sood, A. K. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J. Clin. Oncol. 30, 4026-4034 (2012).
17. Li, Q. et al. The therapeutic efficacy of anti-vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin. Cancer Res. 13, 5918-5925 (2007).
18. Ikuta, K. et al. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. Clin. Cancer Res. 15, 7229-7237 (2009).
19. Yano, S. et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am. J. Pathol. 157, 1893-1903 (2000).
20. Yano, S. et al. Multifunctional interleukin-1beta promotes metastasis of human lung cancer cells in SCID mice via enhanced expression of adhesion-, invasionand angiogenesis-related molecules. Cancer Sci. 94, 244-252 (2003).
21. Guagnano, V. et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVPBGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem. 54, 7066-7083 (2011).
22. Reilkoff, R. A., Bucala, R. & Herzog, E. L. Fibrocytes: emerging effector cells in chronic inflammation. Nat. Rev. Immunol. 11, 427-435 (2011).
23. Pilling, D., Fan, T., Huang, D., Kaul, B. & Gomer, R. H. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS ONE 4, e7475 (2009).
24. Hartlapp, I. et al. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J. 15, 2215-2224 (2001).
25. De Clercq, E. The bicyclam AMD3100 story. Nat. Rev. Drug Discov. 2, 581-587 (2003).
26. Broxmeyer, H. E. et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp Med. 201, 1307-1318 (2005).
27. Azab, A. K. et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113, 4341-4351 (2009).
28. Ceradini, D. J. et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med 10, 858-864 (2004).
29. Singh, S. R. et al. CCL2 release by airway smooth muscle is increased in asthma and promotes fibrocyte migration. Allergy 69, 1189-1197 (2014).
30. Phillips, R. J. et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J. Clin. Invest. 114, 438-446 (2004).
31. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005).
32. Mancuso, M. R. et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116, 2610-2621 (2006).
33. Chung, A. S. et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat. Med. 19, 1114-1123 (2013).
34. Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M. & Cerami, A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1, 71-81 (1994).
35. Bellini, A. & Mattoli, S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab. Invest. 87, 858-870 (2007).
36. Chesney, J., Metz, C., Stavitsky, A. B., Bacher, M. & Bucala, R. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J. Immunol. 160, 419-425 (1998).
37. Gomperts, B. N. & Strieter, R. M. Fibrocytes in lung disease. J. Leukoc. Biol. 82, 449-456 (2007).
38. Rock, J. R. et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc. Natl Acad. Sci. USA 108, E1475-E1483 (2011).
39. Sangaletti, S. et al. SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage. Am. J. Pathol. 179, 3000-3010 (2011).
40. Aono, Y. et al. Surfactant protein D regulates effector cell function and fibrotic ung remodeling in response to bleomycin injuruy. Am. J. Respir. Crit. Care Med. 185, 525-536 (2012).
41. Yeager, M. E. et al. Circulating fibrocytes are increased in children and young adults with pulmonary hypertension. Eur. Respir. J. 39, 104-111 (2012).
42. Wang, C. H. et al. Increased circulating fibrocytes in asthma with chronic airflow obstruction.. Am. J. Respir. Crit. Care Med. 178, 583-591 (2008).
43. Medbury, H. J. et al. Monocytes contribute to the atherosclerotic cap by transformation into fibrocytes. Int. Angiol. 27, 114-123 (2008).
44. Mathai, S. K. et al. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab. Invest. 90, 812-823 (2010).
45. Galligan, C. L. & Fish, E. N. Circulating fibrocytes contribute to the pathogenesis of collagen antibody-induced arthritis. Arthritis Rheum. 64, 3583-3593 (2012).
46. Zhang, H. et al. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood 122, 1105-1113 (2013).
47. Willett, C. G. et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J. Clin. Oncol. 27, 3020-3026 (2009).
48. Dowlati, A. et al. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab: an Eastern Cooperative Oncology Group study. Clin. Cancer Res. 14, 1407-1412 (2008).
49. Kopetz, S. et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol. 28, 453-459 (2010).
50. Baar, J. et al. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin. Cancer Res. 15, 3583-3590 (2009).
51. Boige, V. et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist 17, 1063-1072 (2012).
52. Loupakis, F. et al. Pharmacodynamic and pharmacogenetic angiogenesisrelated markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br. J. Cancer 104, 1262-1269 (2011).
53. Casanovas, O., Hicklin, D. J., Bergers, G. & Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309 (2005).
54. Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. & Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287-1295 (2003).
55. Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 (2007).
56. Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer. 4, 71-78 (2004).
57. De Palma, M. et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8, 211-226 (2005).
58. Hattori, K. et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat. Med 8, 841-849 (2002).
59. Kaplan, R. N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820-827 (2005).
60. Bunt, S. K., Sinha, P., Clements, V. K., Leips, J. & Ostrand-Rosenberg, S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176, 284-290 (2006).
61. Yang, L. et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6, 409-421 (2004).
62. Shi, Y. et al. Deficiency of Kruppel-like factor KLF4 in myeloid-derived suppressor cells inhibits tumor pulmonary metastasis in mice accompanied by decreased fibrocytes. Oncogenesis 3, e129 (2014).
63. Nakataki, E. et al. Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. Cancer Sci. 97, 183-191 (2006).
64. Yano, S. et al. Novel metastasis model of human lung cancer in SCID mice depleted of NK cells. Int. J. Cancer 67, 211-217 (1996).
65. Yano, S. et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin. Cancer Res. 6, 957-965 (2000).
66. Weidner, N., Semple, J. P., Welch, W. R. & Folkman, J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med. 324, 1-8 (1991).
67. Aono, Y. et al. Role of platelet-derived growth factor/platelet-derived growth factor receptor axis in the trafficking of circulating fibrocytes in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 51, 793-801 (2014).
68. Nishioka, Y., Nishimura, N., Suzuki, Y. & Sone, S. Human monocyte-derived and CD83(+) blood dendritic cells enhance NK cell-mediated cytotoxicity. Eur. J. Immunol. 31, 2633-2641 (2001).
69. Moore, B. B. et al. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am. J. Pathol. 166, 675-684 (2005).